Evidence map›Paper›PMID 41282875›Full record

ArticlemedRxiv : the preprint server for health sciences2025

Second-line therapy following osimertinib in metastatic

Michael Rafizadeh, Stephanie Bogdan, Jonathan Lee, Christine Garcia, Ashish Saxena, Kathy Zhou, Bobak Parang

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Michael RafizadehDivision of Hematology and Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY.
Stephanie BogdanDivision of Hematology and Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY.
Jonathan LeeDivision of Hematology and Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY.
Christine GarciaDivision of Hematology and Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY.
Ashish SaxenaDivision of Hematology and Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY.
Kathy ZhouDepartment of Population Health Sciences, Weill Cornell Medicine, New York, NY.
Bobak ParangDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH.

Funding

The Role of Propionate Metabolism in Non-Small Cell Lung CancerK08CA279653 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI Bobak Parang · 2024 to 2026
$579k
NCI NIH HHS K08 CA279653
6 · The paper itself

Abstract

Purpose: FLAURA2 demonstrated that adding chemotherapy to osimertinib improved overall survival compared with osimertinib monotherapy in metastatic Patients and Methods: This is a retrospective cohort study of 115 patients with metastatic Results: Most patients were female (74%) and had a history of never-smoking (69%). Fifty percent were Asian, and 93% of patients had adenocarcinoma histology. The median time to treatment failure (TTF) for all patients on first-line osimertinib was 25.3 months (95% CI: 18.6-37.5). The median TTF was 16.3 months (CI: 13.3-22.0) for Conclusions: Only 61% of patients with metastatic

Indexed as

EGFRFLAURA2non-small cell lung cancerosimertinibsecond line therapy

Identifiers

PMID41282875
PMCPMC12636672

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.